EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years

Erick F Mayer iD, Ann R Falsey iD, Rebecca Clark, Murdo Ferguson, Jose Cardona, Fahua She, Barbara Jones, Caroline Reuter, Avi Collins, Anisha Mannan, Archana Kapoor, Karen Slobod und 9 weitere

Clinical Infectious Diseases · 04.02.2026 · 81 (6) · e708-e716

DOI: 10.1093/cid/ciaf292 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.06.2025. Verfasst von Erick F Mayer und 20 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Immunogenicity, Vaccine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is a significant health risk for adults aged 18–59 years with chronic medical conditions.

Methods

This ongoing, randomized, double-blind phase 3 trial evaluates safety and immunogenicity of the RSV vaccine, mRNA-1345, in adults aged 18–59 years at increased risk for RSV-associated lower respiratory tract disease (LRTD). Participants received a single 50-µg (licensed dose) or 30-µg dose. Co-primary immunogenicity objectives were to demonstrate noninferiority of day 29 RSV-A/B neutralizing antibody (nAb) geometric mean titers (GMTs) for the 50-μg dose compared with those observed in adults aged ≥60 years from the phase 3 pivotal efficacy trial. The other primary objective was to evaluate safety and tolerability.

Results

A total of 999 participants received mRNA-1345 (50 µg, n = 502; 30 µg, n = 497). Most solicited adverse reactions (ARs) were mild to moderate with a median duration of 2 days. Day 29 nAb GMTs in the 50-µg group met noninferiority criteria: RSV-A GMT ratio (GMR), 1.2 (95% confidence interval [CI], 1.1–1.3); RSV-B GMR, 1.1 (95% CI, 1.0–1.2). Noninferiority was also demonstrated for seroresponse rate differences: RSV-A, 11.8% (95% CI, 7.8–15.5); RSV-B, 10.8% (95% CI, 5.9–15.6). Immune responses were consistent across subgroups and remained above baseline through day 181.

Conclusions

In adults aged 18–59 years at increased risk for RSV-LRTD, a 50-µg dose of mRNA-1345 was well tolerated and elicited RSV-A and RSV-B nAb responses noninferior to those observed in older adults in the pivotal study, supporting inference of efficacy in this population. Clinical Trials Registration NCT06067230

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanImmunogenicity, VaccineHumansAdultMiddle AgedMaleAdolescentYoung AdultFemaleDouble-Blind MethodAntibodies, ViralAntibodies, NeutralizingmRNA Vaccines

Stichwörter der Autor:innen

immunogenicitymRNA RSV vaccinerespiratory syncytial virussafety

Substanzen

Antibodies, ViralAntibodies, NeutralizingRespiratory Syncytial Virus VaccinesmRNA-1345 respiratory syncytial virus vaccinemRNA Vaccines

Autor:innen und Institutionen

  • Moderna, Inc, Cambridge, Massachusetts, USA.
  • University of Rochester School of Medicine, Rochester, New York, USA.
  • Department of Clinical Research, Layton Medical Centre, Blackpool, United Kingdom.
  • Department of Family Medicine and Emergency Medicine, Colchester Research Group, Truro, Nova Scotia, Canada.
  • Indago Research, Hialeah, Florida, USA.
  • Cambridge ID & Immunology Consulting, LLC, Somerville, Massachusetts, USA.

ORCID-Profile: Erick F Mayer, Ann R Falsey, Eleanor Wilson, Frances Priddy

Förderung

  • Moderna, Inc

Zitieren

APA

Mayer, E. F., Falsey, A. R., Clark, R., Ferguson, M., Cardona, J., She, F., Jones, B., Reuter, C., Collins, A., Mannan, A., Kapoor, A., Slobod, K., Stoszek, S. K., Du, J., Mou, J., Lan, L., Zhou, H., Wilson, E., Goswami, J., …, & Priddy, F. (2026). Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years. Clinical Infectious Diseases, 81(6), e708-e716. https://doi.org/10.1093/cid/ciaf292

Vancouver

Mayer EF, Falsey AR, Clark R, Ferguson M, Cardona J, She F, et al. Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years. Clinical Infectious Diseases. 2026;81(6):e708-e716. doi:10.1093/cid/ciaf292

BibTeX
@article{Mayer2026,
  author = {Mayer, Erick F and Falsey, Ann R and Clark, Rebecca and Ferguson, Murdo and Cardona, Jose and She, Fahua and Jones, Barbara and Reuter, Caroline and Collins, Avi and Mannan, Anisha and Kapoor, Archana and Slobod, Karen and Stoszek, Sonia K and Du, Jiejun and Mou, Jenni and Lan, Lan and Zhou, Honghong and Wilson, Eleanor and Goswami, Jaya and Das, Rituparna and Priddy, Frances},
  title = {Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {e708--e716},
  doi = {10.1093/cid/ciaf292}
}
Kostenlos starten →